Crossroads of methodological choices in research synthesis: insights from two network meta-analyses on preventing

Giovanni Ostuzzi1, Johannes Schneider-Thoma2, Federico Tedeschi3

  • 1WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Università degli Studi di Verona, Verona, Italy giovanni.ostuzzi@univr.it.

BMJ Mental Health
|May 17, 2023
PubMed

Insights

Network meta-analyses are crucial for clinical guidelines but lack methodological consensus. Different choices in analyzing schizophrenia relapse prevention impact results and interpretation.

Area of Science:

  • Psychiatry and Mental Health
  • Evidence-Based Medicine
  • Statistical Methodology

Background:

  • Network meta-analysis (NMA) is increasingly used for clinical guidelines and policy decisions.
  • Methodological and statistical aspects of NMA are still evolving, leading to varied approaches.
  • Discrepancies in NMA methodology can arise from different research groups' expertise.

Purpose of the Study:

  • To critically assess two NMAs on pharmacological relapse prevention in schizophrenia.
  • To highlight how differing methodological choices influence analysis outcomes.
  • To examine the clinical-epidemiological interpretation of NMA results.

Main Methods:

  • Comparative analysis of two distinct NMAs on schizophrenia relapse prevention.
  • Focus on methodological and statistical choices made by different research groups.
  • Discussion of key technical issues in NMA, including transitivity assessment.

Main Results:

  • Methodological variations in NMAs can lead to different conclusions regarding treatment efficacy.
  • The choice of statistical methods and assumptions significantly impacts the interpretation of results.
  • Lack of consensus on issues like transitivity assessment complicates direct comparisons.

Conclusions:

  • Standardized methodological guidelines for NMAs are needed for consistent and reliable evidence synthesis.
  • Researchers must carefully consider and report methodological choices in NMAs.
  • Further research is required to address unresolved methodological challenges in NMA.

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
149
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
75
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
106
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
778
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
172
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
151